Pediatric News, May 2008 The FDA approved a new age range for a new formulation of Prilosec. The delayed-release oral suspension is indicated for short-term treatment of symptoms of gastroesophageal reflux disorder and healing of erosive esophagitis in children aged 1-2 years. "This [official approval] makes everyone feel better because the studies are completed and we are using the medication for the right indication, versus having to extrapolate from adult data," Dr. Xavier Villa said. "In that way it's a very good thing. I wish more companies would get medication approvals in kids." Villa is director of the UTMB division of pediatric gastroenterology, hepatology, and nutrition.